As­traZeneca pays $25M up­front, $80M eq­ui­ty in­vest­ment in­to Cel­lec­tis for gene and cell ther­a­py pact

As­traZeneca is beef­ing up its cell and gene ther­a­py po­ten­tial by col­lab­o­rat­ing with and in­vest­ing in French biotech Cel­lec­tis, start­ing out with a $25 mil­lion up­front pay­ment and an $80 mil­lion eq­ui­ty in­vest­ment.

As­traZeneca will pay Cel­lec­tis $105 mil­lion to­tal in the last quar­ter of this year, tak­ing over a 22% stake in Cel­lec­tis and 21% of vot­ing rights. As it buys up 16 mil­lion shares at $5 per share, As­traZeneca will al­so be able to add a non-vot­ing ob­serv­er to the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER